WINTHER & SPRING: Targeted agents and triple agent combinations

Precision medicine in newly diagnosed breast cancer

Implementing precision medicine in oncology: The IMPACT trials

Lessons from long-term survey of stage I NSCLC

Editor's Choice for June 2018

Editor’s Choice for May 2018

Diagnosis and management of smouldering myeloma

Phase I taselisib results and a cell-free DNA assay

Impact of microbiome on head and neck cancers

First-in-human trial results of RET targeted BLU-667

Treating RET alterations with novel therapy BLU-667

Tandem duplications in triple negative breast cancer